Cobimetinib

Overview

Cobimetinib is a mitogen-activated protein kinase inhibitor that blocks chemicals in the cancer cell responsible for growth and division.

SparkCures ID 251
Developed By Exelixis
Generic Name Cobimetinib
Additional Names Cotellic, GDC-0973, XL-518
Treatment Classifications
  • MEK Inhibitor

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.